title: Focus on risperidone.
abstract: Risperidone is a relatively new antipsychotic available world-wide since the early 1990s. It has been characterised as atypical, but shares some of the extrapyramidal side-effect profile of the earlier antipsychotics, when used at doses higher than those recommended by the manufacturer (4-6 mg/day). There is now adequate comparison with conventional antipsychotics to suggest its superiority, but a depot formulation is needed to complete the picture.
authors.affiliation: University of Liverpool, UK. bengreen@liverpool.ac.uk
authors.forename: B
authors.initials: B
authors.lastname: Green
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D011618:Psychotic Disorders / Q000188:drug therapy; D018967:Risperidone / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D006220:Haloperidol; D018967:Risperidone